Navigation Links
WallSt.net Announces Upcoming Interview With CEO Of Immunosyn Corporation
Date:11/14/2007

LA JOLLA, Calif., Nov. 14 /PRNewswire-FirstCall/ -- Stephen D. Ferrone, CEO of Immunosyn Corporation (OTC Bulletin Board: IMYN) will be featured in an exclusive interview with http://www.wallst.net scheduled for November 16 at 8:00 A.M. PST. The interview will be posted on http://www.wallst.net by 5 P.M. EST on November 16, 2007.

The interview will cover topics including Immunosyn's market potential, growth initiatives, competitive edge, recent news and milestones that investors should watch for.

"This interview is a part of our strategic market communication plan which includes meeting with brokers and institutional managers as well as taking part in interviews," says Stephen D. Ferrone, CEO and President of Immunosyn.

To hear the interview in its entirety, visit http://wallst.net and click on "Interviews." The interview can be accessed by locating the company's ticker symbol (IMYN) under the appropriate exchange (OTCBB) at the top of the "Interviews" section or by entering the company's ticker symbol (IMYN) in the Search Archive window.

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and
'/>"/>

SOURCE Immunosyn Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of Osteologix
2. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
3. WallSt.net Announces Upcoming Interview with CEO of BioSante Pharmaceuticals
4. WallSt.net Announces Upcoming Interview With CEO of Biomoda
5. Synvista Therapeutics to be Featured on Wallst.net
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 2015   For the seventh year running, Across Health ... overall digital maturity called the Multichannel Maturometer . ... not maturing fast enough. While it,s true that technology ... overall and customers are increasingly "digital natives", pharma still ... engagement.  ...
(Date:6/26/2015)... , June 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced that all nominees listed in the management ... at its 2015 Annual Meeting of Shareholders, held ... by ballot, the following 5 nominees proposed by ... to serve until the Company,s next Annual Meeting ...
(Date:6/26/2015)... (PRWEB) , ... June 26, 2015 , ... ... today announced that its SimplePrep™ technologies have been integrated into a sample prep ... Space Station (ISS) as a part of the NASA’s WetLab-2 Project. , On ...
(Date:6/26/2015)... ... ... ReliantHeart, Inc. , an innovative supplier of advanced mechanical circulatory assist technologies ... (HA5) to the 68th consecutive implant, there has been no evidence of de novo ... referred to as de novo thrombus. De novo thrombus can hide under the impeller ...
Breaking Biology Technology:Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 2Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 3HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 2HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 3
... Calif., July 27, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... and accomplishments. For the second quarter ended ... $10.3 million, or $0.20 per share, compared to a net ... same period in 2010. As of June 30, 2011, the ...
... Corporation , a leading global provider of microwave laboratory ... microwave peptide synthesis products . In FY2011 year-to-date, the ... in its automated peptide synthesizer instrument sales and is ... systems. Additionally, CEM,s products were well received at the ...
... 2011 Linden LLC, a Chicago-based healthcare private ... an investment in Strata Pathology Services, Inc., a ... Headquartered in Lexington, Massachusetts, Strata offers ... oral pathology, gastroenterology and gynecology segments. Since 1984, ...
Cached Biology Technology:Sangamo BioSciences Reports Second Quarter 2011 Financial Results 2Sangamo BioSciences Reports Second Quarter 2011 Financial Results 3Sangamo BioSciences Reports Second Quarter 2011 Financial Results 4Sangamo BioSciences Reports Second Quarter 2011 Financial Results 5Sangamo BioSciences Reports Second Quarter 2011 Financial Results 6Sangamo BioSciences Reports Second Quarter 2011 Financial Results 7Record Year for CEM's Peptide Synthesis Business 2Record Year for CEM's Peptide Synthesis Business 3Linden Enters Anatomic Pathology Sector Through Investment in Strata Pathology Services, Inc. 2
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
(Date:6/24/2015)... Biometry authentication provider KeyLemon today announced ... one face in. Logo - ... in, entering the expanding biometric authentication market in ... answer to the password problem. With advanced face ... KeyLemon, one face in allows users to securely ...
(Date:6/18/2015)... , June 18, 2015 This report ... Million by the following Product Segments, which includes Immunoassay ... Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay ... US, Canada , Japan ... Asia-Pacific , Latin America , ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... Madison, WI, February 24, 2009 | Tiny sediment grains ... minerals in an open fabric that results in a ... grains. Scientists at the U.S. Geological Survey (USGS) are ... composition of these coatings on sediment grains in the ...
... with the tiny fruit fly and then moving into mice and ... of the same gene suppresses cancer in all three organisms. Reciprocally, ... in mammals leads to cancer. The authors show there is ... with a drug. They report their findings in two papers in ...
... today (Monday) to advise the country on how it ... The biotechonology experts from the Belfast-based University are ... cost the world economy around $200 billion in lost ... year. A delegation led by Dr Gerry Brennan ...
Cached Biology News:Ultra-fine coatings on sediment grains influence nitrate and sulfate storage in soil 2Suppressing cancer with a master control gene 2Reduction in parasite infections ahead for India 2